These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 26204202)

  • 1. Clinical and Dosimetric Variables Related to Outcome After Treatment of Graves' Disease With 550 and 1110 MBq of 131I: Results of a Prospective Randomized Trial.
    Sapienza MT; Coura-Filho GB; Willegaignon J; Watanabe T; Duarte PS; Buchpiguel CA
    Clin Nucl Med; 2015 Sep; 40(9):715-9. PubMed ID: 26204202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalization of radioiodine treatment for Graves' disease: a prospective, randomized study with a novel method for calculating the optimal 131I-iodide activity based on target reduction of thyroid mass.
    Orsini F; Traino AC; Grosso M; Guidoccio F; Boni G; Volterrani D; Mariani G
    Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):496-502. PubMed ID: 23358401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Graves' disease radioiodine-therapy: choosing target absorbed doses for therapy planning.
    Willegaignon J; Sapienza MT; Coura-Filho GB; Watanabe T; Traino AC; Buchpiguel CA
    Med Phys; 2014 Jan; 41(1):012503. PubMed ID: 24387527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
    Giovanella L; De Palma D; Ceriani L; Vanoli P; Garancini S; Tordiglione M; Tarolo GL
    Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study.
    Howarth D; Epstein M; Lan L; Tan P; Booker J
    Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possibility of limiting the un-justified irradiation in (131)I therapy of Graves' disease: a thyroid mass-reduction based method for the optimum activity calculation.
    Traino AC; Grosso M; Mariani G
    Phys Med; 2010 Apr; 26(2):71-9. PubMed ID: 19800827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study of the possibility of curing Graves' disease based on the desired reduction of thyroid mass (volume) as a consequence of 131I therapy: a speculative paper.
    Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
    Nucl Med Commun; 2006 May; 27(5):439-46. PubMed ID: 16609355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A practical method for the estimation of therapeutic activity in the treatment of Graves' hyperthyroidism.
    Panareo S; Rossi R; Fabbri S; De Paola G; Candini GC; Feggi L; Degli Uberti E
    Q J Nucl Med Mol Imaging; 2011 Oct; 55(5):576-85. PubMed ID: 21068711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of different thyroid committed doses in radioiodine therapy for Graves' hyperthyroidism.
    Grosso M; Traino A; Boni G; Banti E; Della Porta M; Manca G; Volterrani D; Chiacchio S; AlSharif A; Borsò E; Raschillà R; Di Martino F; Mariani G
    Cancer Biother Radiopharm; 2005 Apr; 20(2):218-23. PubMed ID: 15869459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
    Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
    Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dosimetric approach to patient-specific radioiodine treatment of Graves' disease with incorporation of treatment-induced changes in thyroid mass.
    Traino AC; Di Martino F; Lazzeri M
    Med Phys; 2004 Jul; 31(7):2121-7. PubMed ID: 15305466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome.
    Reinhardt MJ; Brink I; Joe AY; Von Mallek D; Ezziddin S; Palmedo H; Krause TM
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1118-24. PubMed ID: 12192554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
    Franklyn JA; Daykin J; Holder R; Sheppard MC
    QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A NTCP approach for estimating the outcome in radioiodine treatment of hyperthyroidism.
    Strigari L; Sciuto R; Benassi M; Bergomi S; Nocentini S; Maini CL
    Med Phys; 2008 Sep; 35(9):3903-10. PubMed ID: 18841841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Characterization of therapy failures in radioiodine therapy of Graves' disease without simultaneous antithyroid agents].
    Sabri O; Zimny M; Schreckenberger M; Reinartz P; Nowak B; Ostwald E; Schäfer W; Block S; Setani K; Büll U
    Nuklearmedizin; 2001 Feb; 40(1):1-6. PubMed ID: 11373933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
    Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative evaluation of two fixed doses of 185 and 370 MBq 131I, for the treatment of Graves' disease resistant to antithyroid drugs.
    Esfahani AF; Kakhki VR; Fallahi B; Eftekhari M; Beiki D; Saghari M; Takavar A
    Hell J Nucl Med; 2005; 8(3):158-61. PubMed ID: 16390021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thyroid echogenicity predicts outcome of radioiodine therapy in patients with Graves' disease.
    Markovic V; Eterovic D
    J Clin Endocrinol Metab; 2007 Sep; 92(9):3547-52. PubMed ID: 17609305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maximum dose rate is a determinant of hypothyroidism after 131I therapy of Graves' disease but the total thyroid absorbed dose is not.
    Krohn T; Hänscheid H; Müller B; Behrendt FF; Heinzel A; Mottaghy FM; Verburg FA
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4109-15. PubMed ID: 25033065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimized radioiodine therapy for Graves' disease: two MIRD-based models for the computation of patient-specific therapeutic 131I activity.
    Carlier T; Salaun PY; Cavarec MB; Valette F; Turzo A; Bardiès M; Bizais Y; Couturier O
    Nucl Med Commun; 2006 Jul; 27(7):559-66. PubMed ID: 16794516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.